Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 4INTERVENTIONAL

Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome

Evaluating TRYPTYR as a Novel Therapy for Dry Eye in Patients With Sjögren's Syndrome

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.

Who May Be Eligible (Plain English)

Who May Qualify: Subjects must fulfill the following conditions to qualify for enrollment into the trial 1. Adults over 18 years old with a diagnosis of dry eye disease (DED) secondary to Sjögren's Syndrome within the past 2 years. 2. History of using or desiring artificial tears for DED symptoms within the past 2 months. 3. Unanesthetized Schirmer's Test (UA ST) score ≥1 and \< 10 mm/5 min and baseline total Corneal Fluorescein Staining (tCFS) score ≥2 and ≤ 15 (National Eye Institute, NEI, grading scale). Who Should NOT Join This Trial: Subjects with any of the following conditions on the eligibility exam may NOT be enrolled into the trial. 1. History of ocular surgery within the past 6 months. 2. Contact lens wear in either eye within 7 days of visit 1 (baseline) or use during study 3. On current topical treatment regimen for less than 3 months or anticipates any change to the regimen during the study period. 4. Use of topical steroid ocular medication or varenicline nasal spray within 4 weeks of baseline or during the study period. 5. Use of artificial tears within 2 hours prior to the baseline or study visit days. 6. Any known allergies to any component of the study drug. 7. Severe, uncontrolled autoimmune conditions (where your immune system attacks your own body) (e.g., rheumatoid arthritis, lupus). Uncontrolled is at the discretion of the PI. Subjects with severe systemic symptoms will not be included. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Subjects must fulfill the following conditions to qualify for enrollment into the trial 1. Adults over 18 years old with a diagnosis of dry eye disease (DED) secondary to Sjögren's Syndrome within the past 2 years. 2. History of using or desiring artificial tears for DED symptoms within the past 2 months. 3. Unanesthetized Schirmer's Test (UA ST) score ≥1 and \< 10 mm/5 min and baseline total Corneal Fluorescein Staining (tCFS) score ≥2 and ≤ 15 (National Eye Institute, NEI, grading scale). Exclusion Criteria: Subjects with any of the following conditions on the eligibility exam may NOT be enrolled into the trial. 1. History of ocular surgery within the past 6 months. 2. Contact lens wear in either eye within 7 days of visit 1 (baseline) or use during study 3. On current topical treatment regimen for less than 3 months or anticipates any change to the regimen during the study period. 4. Use of topical steroid ocular medication or varenicline nasal spray within 4 weeks of baseline or during the study period. 5. Use of artificial tears within 2 hours prior to the baseline or study visit days. 6. Any known allergies to any component of the study drug. 7. Severe, uncontrolled autoimmune disease (e.g., rheumatoid arthritis, lupus). Uncontrolled is at the discretion of the PI. Subjects with severe systemic symptoms will not be included.

Treatments Being Tested

DRUG

TRYPTYR (Acoltremon ophthalmic solution 0.003%)

Drop to be instilled before and after endpoint measurement.

Locations (1)

Center For Sight
Venice, Florida, United States